Hantaviruses Direct Endothelial Cell Permeability by Sensitizing Cells to the Vascular Permeability Factor VEGF, while Angiopoietin 1 and Sphingosine 1-Phosphate Inhibit Hantavirus-Directed Permeability
ABSTRACT
Hantaviruses infect human endothelial cells and cause two vascular permeability-based diseases: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Hantavirus infection alone does not permeabilize endothelial cell monolayers. However, pathogenic hantaviruses inhibit the function of αvβ3 integrins on endothelial cells, and hemorrhagic disease and vascular permeability deficits are consequences of dysfunctional β3 integrins that normally regulate permeabilizing vascular endothelial growth factor (VEGF) responses. Here we show that pathogenic Hantaan, Andes, and New York-1 hantaviruses dramatically enhance the permeability of endothelial cells in response to VEGF, while the nonpathogenic hantaviruses Prospect Hill and Tula have no effect on endothelial cell permeability. Pathogenic hantaviruses directed endothelial cell permeability 2 to 3 days postinfection, coincident with pathogenic hantavirus inhibition of αvβ3 integrin functions, and hantavirus-directed permeability was inhibited by antibodies to VEGF receptor 2 (VEGFR2). These studies demonstrate that pathogenic hantaviruses, similar to αvβ3 integrin-deficient cells, specifically enhance VEGF-directed permeabilizing responses. Using the hantavirus permeability assay we further demonstrate that the endothelial-cell-specific growth factor angiopoietin 1 (Ang-1) and the platelet-derived lipid mediator sphingosine 1-phosphate (S1P) inhibit hantavirus directed endothelial cell permeability at physiologic concentrations. These results demonstrate the utility of a hantavirus permeability assay and rationalize the testing of Ang-1, S1P, and antibodies to VEGFR2 as potential hantavirus therapeutics. The central importance of β3 integrins and VEGF responses in vascular leak and hemorrhagic disease further suggest that altering β3 or VEGF responses may be a common feature of additional viral hemorrhagic diseases. As a result, our findings provide a potential mechanism for vascular leakage after infection by pathogenic hantaviruses and the means to inhibit hantavirus-directed endothelial cell permeability that may be applicable to additional vascular leak syndromes.
Top-30
Journals
|
2
4
6
8
10
12
14
16
18
20
|
|
|
Journal of Virology
19 publications, 13.77%
|
|
|
Viruses
9 publications, 6.52%
|
|
|
Antiviral Research
6 publications, 4.35%
|
|
|
Virus Research
5 publications, 3.62%
|
|
|
Frontiers in Microbiology
4 publications, 2.9%
|
|
|
PLoS Pathogens
4 publications, 2.9%
|
|
|
Virulence
4 publications, 2.9%
|
|
|
mBio
4 publications, 2.9%
|
|
|
BMC Infectious Diseases
3 publications, 2.17%
|
|
|
Virology
3 publications, 2.17%
|
|
|
Advances in Virology
3 publications, 2.17%
|
|
|
Journal of General Virology
2 publications, 1.45%
|
|
|
International Journal of Molecular Sciences
2 publications, 1.45%
|
|
|
Cells
2 publications, 1.45%
|
|
|
Frontiers in Cellular and Infection Microbiology
2 publications, 1.45%
|
|
|
Frontiers in Immunology
2 publications, 1.45%
|
|
|
PLoS ONE
2 publications, 1.45%
|
|
|
Infectious Disorders - Drug Targets
1 publication, 0.72%
|
|
|
Future Virology
1 publication, 0.72%
|
|
|
Tissue Engineering - Part A.
1 publication, 0.72%
|
|
|
Tissue Engineering - Part B: Reviews
1 publication, 0.72%
|
|
|
Lymphatic Research and Biology
1 publication, 0.72%
|
|
|
Medicine (United States)
1 publication, 0.72%
|
|
|
Journal of International Medical Research
1 publication, 0.72%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 0.72%
|
|
|
Frontiers in Medicine
1 publication, 0.72%
|
|
|
Archives of Virology
1 publication, 0.72%
|
|
|
Inflammation
1 publication, 0.72%
|
|
|
Nature Reviews Microbiology
1 publication, 0.72%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
33 publications, 23.91%
|
|
|
American Society for Microbiology
23 publications, 16.67%
|
|
|
MDPI
13 publications, 9.42%
|
|
|
Springer Nature
12 publications, 8.7%
|
|
|
Frontiers Media S.A.
10 publications, 7.25%
|
|
|
Taylor & Francis
7 publications, 5.07%
|
|
|
Public Library of Science (PLoS)
6 publications, 4.35%
|
|
|
Hindawi Limited
6 publications, 4.35%
|
|
|
Wiley
4 publications, 2.9%
|
|
|
Mary Ann Liebert
3 publications, 2.17%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 2.17%
|
|
|
Microbiology Society
2 publications, 1.45%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 1.45%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.72%
|
|
|
SAGE
1 publication, 0.72%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.72%
|
|
|
American Society of Nephrology
1 publication, 0.72%
|
|
|
National Institute of Infectious Diseases
1 publication, 0.72%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.72%
|
|
|
American Society of Hematology
1 publication, 0.72%
|
|
|
LLC Numicom
1 publication, 0.72%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.72%
|
|
|
Federal Center for Hygiene and Epidemiology
1 publication, 0.72%
|
|
|
IOP Publishing
1 publication, 0.72%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.72%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.72%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.